98%
921
2 minutes
20
Variational Inference (VI) is a commonly used technique for approximate Bayesian inference and uncertainty estimation in deep learning models, yet it comes at a computational cost, as it doubles the number of trainable parameters to represent uncertainty. This rapidly becomes challenging in high-dimensional settings and motivates the use of alternative techniques for inference, such as Monte Carlo Dropout (MCD) or Spectral-normalized Neural Gaussian Process (SNGP). However, such methods have seen little adoption in survival analysis, and VI remains the prevalent approach for training probabilistic neural networks. In this paper, we investigate how to train deep probabilistic survival models in large datasets without introducing additional overhead in model complexity. To achieve this, we adopt three probabilistic approaches, namely VI, MCD, and SNGP, and evaluate them in terms of their prediction performance, calibration performance, and model complexity. In the context of probabilistic survival analysis, we investigate whether non-VI techniques can offer comparable or possibly improved prediction performance and uncertainty calibration compared to VI. In the MIMIC-IV dataset, we find that MCD aligns with VI in terms of the concordance index (0.748 vs. 0.743) and mean absolute error (254.9 vs. 254.7) using hinge loss, while providing C-calibrated uncertainty estimates. Moreover, our SNGP implementation provides D-calibrated survival functions in all datasets compared to VI (4/4 vs. 2/4, respectively). Our work encourages the use of techniques alternative to VI for survival analysis in high-dimensional datasets, where computational efficiency and overhead are of concern.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1109/JBHI.2024.3417369 | DOI Listing |
J Eval Clin Pract
September 2025
Department of Orthopedics and Traumatology, Medical Faculty, University of Health Sciences, Antalya, Turkey.
Aims And Objective: The field of medical statistics has experienced significant advancements driven by integrating innovative statistical methodologies. This study aims to conduct a comprehensive analysis to explore current trends, influential research areas, and future directions in medical statistics.
Methods: This paper maps the evolution of statistical methods used in medical research based on 4,919 relevant publications retrieved from the Web of Science.
Anticancer Drugs
September 2025
Department of Blood and Marrow Transplantation, Tianjin Cancer Hospital Airport Hospital, National Clinical Research Center for Cancer.
Bortezomib resistance in multiple myeloma (MM) is a significant clinical challenge that limits the long-term effectiveness. Currently, there is a lack of reliable biomarkers to predict bortezomib resistance. Previous studies reported that several proteins regulate bortezomib resistance through targeting ubiquitin-proteasome pathways, including heat shock protein family A member 9 (HSPA9), dickkopf Wnt signaling pathway inhibitor 1 (DKK1), proteasome 26S subunit non-ATPase 14 (PSMD14), and tripartite motif containing 21 (TRIM21).
View Article and Find Full Text PDFGut Liver
September 2025
Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
Background/aims: Despite medical advances in recent decades, the mortality rate of advanced liver cirrhosis remains high. Although liver transplantation remains the most effective treatment, candidate selection is limited by donor availability and alcohol abstinence requirements. Bone marrow-derived mesenchymal stem cell (BM-MSC) transplantation has shown promise for the treatment of advanced cirrhosis.
View Article and Find Full Text PDFHistol Histopathol
September 2025
Institute of Pathology, University Hospital Bonn, Bonn, Germany.
Aims: We aimed to analyze CD63, a cell surface protein that has been associated with tumor aggressiveness in several cancers, including breast, colorectal, and lung cancer, as well as melanoma, in prostate cancer.
Methods: CD63 expression was analyzed immunohistochemically in a cohort of primary prostate cancers from 281 patients. The results were correlated with clinico-pathologic parameters, including biochemical recurrence.
BMB Rep
September 2025
Basic Research Laboratory, Department of Physiology, College of Medicine, Smart Marine Therapeutic Center, Cardiovascular and Metabolic Disease Core Research Center, Inje University, Busan 47392, Korea; Department of Health Science and Technology, College of Medicine, Inje University, Busan 47392, K
Patients with multiple myeloma develop resistance to thalidomide during therapy, and the mechanisms to counteract thalidomide resistance remain elusive. Here, we explored the interaction between cereblon and mitochondrial function to mitigate thalidomide resistance in multiple myeloma. Measurements of cell viability, ATP production, mitochondrial membrane potential, mitochondrial ROS, and protein expression via western blotting were conducted in vitro using KSM20 and KMS26 cells to assess the impact of thalidomide on multiple myeloma.
View Article and Find Full Text PDF